바이오테크 보도자료
-
- Asia Specific Biotechnology Instruments Market Is Poised To Exceed USD 40 Bn by 2032; R&D Arms of Major Multinational Pharmaceutical Corporations Fuels The Market: Report by Fact.MR
- The Biotechnology Instruments Market revenues were estimated at USD 46.1 Bn in 2021 and is anticipated to grow at a CAGR of 16.4% from 2022-2032, according to a recently published Fact.MR report. By the end of 2032, the market is expected to reach...
- 2022년 06월 22일
-
- Galderma Announces Positive Data From Phase III Trial, Demonstrating Efficacy and Safety of nemolizumab in Patients with Prurigo Nodularis
- Galderma today announced the phase III OLYMPIA 2 trial met all primary and key secondary endpoints, showing nemolizumab as monotherapy significantly improved skin lesions and pruritus (itch) compared with placebo in adult patients with moderate to...
- 2022년 06월 22일
-
- Waters and BioInfra Establish the ASEAN Academy for Bioanalysis to Promote Analytical Skills Development
- Waters Corporation (NYSE:WAT) announced a collaboration with BioInfra, a pioneering contract research organization (CRO) company for the pharmaceutical and clinical fields, to jointly establish the ASEAN Academy for Bioanalysis. The academy is ded...
- 2022년 06월 21일
-
- Companies in the Global Omics Based Clinical Trials Market Expedite Product Innovations to Stay at Forefront; Expected Sales to Reach USD 61.7 Bn By 2032: Fact.MR’s Study
- The Omics Based Clinical Trials Market revenues were estimated at USD 26.2 Bn in 2021 and is anticipated to grow at a CAGR of 8.1% from 2022 to 2032, according to a recently published Fact.MR report. By the end of 2032, the market is expected to r...
- 2022년 06월 21일
-
- AOP Health Presents Final Results From Its CONTINUATION-PV Study - up to 7.5 Years Treatment With BESREMi® (Ropeginterferon alfa-2b) of Polycythaemia Vera Patients - at EHA 2022 Annual Meeting
- AOP Health announced the final results on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from its CONTINUATION-PV study in an oral presentation at the prestigious EHA (European Hematology Association) 2022 Annual Meeting by Profe...
- 2022년 06월 21일
-
- AOP 헬스, EHA 2022 연례 회의서 ‘CONTINUATION-PV’ 연구 결과 발표… 베스레미(로페그인터페론알파-2b) 이용한 7년 6개월의 진성적혈구증가증 환자 치료 여정 마무리
- AOP 헬스(AOP Health)가 2022년 유럽혈액학회(EHA) 연례 회의에서 진성적혈구증가증(Polycythaemia Vera, 약칭 PV) 환자를 로페그인터페론알파-2b(Ropeginterferon alfa-2b)로 치료하는 ‘CONTINUATION-PV’ 연구의 최종 결과를 구두로 발표했다. 발표는 하인츠 기슬링...
- 2022년 06월 21일
-
- Solasia Pharma: DARVIAS® Injection 135mg (Generic Name: DARINAPARSIN /Development Code: SP-02) Approved in Japan
- Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, hereinafter DARVIAS®) has been approved fo...
- 2022년 06월 20일
-
- IFPMA: Pharmaceutical Industry Expresses Deep Disappointment With Decision on Waiving Intellectual Property Rights Adopted at the World Trade Organization Ministerial Conference
- Today’s decision at the World Trade Organization (WTO) Ministerial Conference (MC12) to endorse a TRIPS waiver for COVID-19 vaccines sends the wrong message to those carrying out research and development and innovating. It incorrectly points to in...
- 2022년 06월 17일
-
- Alvotech, a Global Pureplay Biosimilars Company, to Debut on Nasdaq Under the Ticker ALVO on June 16
- Alvotech, a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide today announced that its ordinary shares and warrants will begin trading on the Nasdaq Stock Market LLC (“Nasdaq”) ...
- 2022년 06월 16일
-
- Saint-Gobain Bioprocess Solutions Business Announces C-Flex® Production Capability in Suwa, Japan
- Saint-Gobain Life Sciences today announced the addition of their Suwa, Japan manufacturing facility for the production of C-Flex® TPE tubing for use in bioprocessing. The capacity addition in Suwa is part of Saint-Gobain Life Sciences ongoing inve...
- 2022년 06월 16일
전시회
